News Pharma Industry

china: China’s neglected generic-drugs industry is looking up. Can it become as significant as India’s?

A worker checks the position of a feeding tray in a pharmaceutical manufacturing truck at the Hengrui Biomedical Industrial Park in East China’s Jiangsu province, December 13, 2021.


After years of development, China’s generic-drugs industry has matured, especially after regulators adopted a “consistency evaluation” system to ensure that the quality and efficacy of generics are equivalent to those of brand-name drugs. Earlier neglected because of slimmer investment returns, this segment is now attracting attention, with the potential to explore markets beyond its boundaries.

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals Co. Ltd. won U.S. regulatory approval in May to market its iodixanol injection for cancer, bringing a long-overdue buzz to China’s silent generic drug industry.Over the past few years, innovative drug development has been vigorously promoted with capital and policies in China. Meanwhile, the generic drug industry has been shrinking due to strict price controls under China’s national drug

  • SAVE

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Source link